Multi-omics clinical study of X-linked adrenoleukodystrophy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064366

Enrollment

Unknown

Registered

2022-10-05

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adrenoleukodystrophy, ALD

Interventions

X-ALD patient group and X-ALD carrier group:None

Eligibility

Sex/Gender

All

Age

6 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Selection criteria of X-linked adrenoleukodystrophy (X-ALD): (1) Conform to X-ALD diagnostic criteria, and the results of gene detection and very long chain fatty acid (VLCFA) were supported; (2) Age: 6-70 years old; (3) Can communicate normally and complete the scale test independently (confirmed by on-site scale test); (4) Signed the informed consent, and volunteer to participate in this research. 2. Selection criteria of carriers: Carriers whose age, gender, education level match the patient group, voluntarily participate in this study and can independently complete the scale test, and meet the following criteria: (1) Asymptomatic carriers aged 6-70 who meet the genetic test and complete the scale test independently (confirmed by on-site scale test); (2) No family genetic disease, no history of mental illness.

Exclusion criteria

Exclusion criteria: Subjects can't be enrolled if they meet any of the following criteria: 1. Other genetic diseases; 2. Other severe central nervous system diseases; 3. Have a history of brain or eye surgery; 4. Depression, anxiety, and other mental diseases; 5. Magnetic resonance examination taboo: Metal foreign body or prosthesis in the body (pacemaker, insulin pump), claustrophobia, and others; 6. Have a history of gastrointestinal-related surgery; 7. Obtain no informed consent; 8. Unable to tolerate MRI or ophthalmologic related examinations.

Design outcomes

Primary

Measure	Time frame
Multi-parameter MRI examination of head;neuropsychiatric inventory,NPI;	—

Secondary

Measure	Time frame
Blood test;urine examination;Stool detection;ophthalmologic examination;	—

Countries

China

Contacts

Public ContactLiang Tan

Department of Neurosurgery, Southwest Hospital, the Army Medical University (Third Military Medical University), Chongqing, China;

tracy200712@hotmail.com+86 15823540630

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026